Sarepta’s Elevidys to Remain on Market With New FDA Warning
Sarepta Therapeutics Inc.’s controversial gene therapy for a rare muscle condition will remain available in the US with a strict…
Tag: Sareptas
Sarepta’s stock plummets as disappointing trial data raise questions on DMD drug’s success
Sarepta’s stock sank after studies of Duchenne muscular dystrophy treatments failed their primary endpoints. www.marketwatch.com #Sareptas #stock #plummets #disappointing #trial…
FDA Investigates Death of Boy Who Got Sarepta’s Gene Therapy
US regulators said they are investigating the death of an 8-year-old boy who received a gene therapy from Sarepta Therapeutics…